No matches

3 search results for: CPUO

The Patient Burden of Chronic Pruritus of Unknown Origin (<b>CPUO</b>)
Dermatology
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)
Infographic

An infographic describing the etiology, epidemiology, challenges in diagnosis and patient burden of CPUO.

View more
Demystifying <b>CPUO</b>: Diagnosis and the Role of Type 2 Inflammation
Dermatology
Demystifying CPUO: Diagnosis and the Role of Type 2 Inflammation
expert video

Join Dr. Brian Kim in discussing the diagnosis of CPUO and the role of type 2 inflammation in disease pathophysiology.

View more
The Role of Type 2 Inflammation Across a Range of Pruritic Skin Diseases in Older Adults
Dermatology
The Role of Type 2 Inflammation Across a Range of Pruritic Skin Diseases in Older Adults
expert video

Dr. Butler explores how type 2 inflammation is a common underlying mechanism in several prevalent chronic pruritic skin conditions affecting the elderly, such as CPUO, AD, BP, and PN

View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region